Literature DB >> 2569468

Deletion and insertion mutants of the multidrug transporter.

S J Currier1, K Ueda, M C Willingham, I Pastan, M M Gottesman.   

Abstract

The multidrug transporter is a 170,000-dalton membrane glycoprotein which confers multidrug resistance through its activity as an ATP-dependent efflux pump for hydrophobic, cytotoxic drugs. To determine the essential structural components of this complex membrane transporter we have altered an MDR1 cDNA in an expression vector by deletion and insertion mutations. The structure of the transporter deduced from its amino acid sequence suggests that it consists of two homologous, perhaps functionally autonomous, halves each with six transmembrane segments and a cytoplasmic ATP-binding domain. However, several carboxyl-terminal deletions, one involving 53 amino acids, the second removing 253 amino acids, and an internal deletion within the carboxyl-terminal half of the molecule, totally eliminate the ability of the mutant transporter to confer drug resistance. An internal deletion of the amino-terminal half, which removed residues 140-229, is also nonfunctional. Small carboxylterminal deletions of up to 23 amino acids leave a functional transporter, although the removal of 23 COOH-terminal amino acids reduces its ability to confer colchicine resistance. Insertions of 4 amino acids in a transmembrane domain, and in one of the two ATP-binding regions, have no effect on activity. These studies define some of the limits of allowable deletions and insertions in the MDR1 gene, and demonstrate the requirement for two intact halves of the molecule for a functional multidrug transporter.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569468

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  A C-terminal tyrosine-based motif in the bile salt export pump directs clathrin-dependent endocytosis.

Authors:  Ping Lam; Shuhua Xu; Carol J Soroka; James L Boyer
Journal:  Hepatology       Date:  2012-04-25       Impact factor: 17.425

2.  Allelic variants of the human putative peptide transporter involved in antigen processing.

Authors:  M Colonna; M Bresnahan; S Bahram; J L Strominger; T Spies
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

Review 3.  Genetic basis of multidrug resistance of tumor cells.

Authors:  S E Kane; I Pastan; M M Gottesman
Journal:  J Bioenerg Biomembr       Date:  1990-08       Impact factor: 2.945

Review 4.  Carrier-mediated intestinal transport of drugs.

Authors:  A Tsuji; I Tamai
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

5.  Identification of new TAP2 alleles in gorilla: evolution of the locus within hominoids.

Authors:  P T Loflin; P R Laud; D I Watkins; D A Lawlor
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

6.  Membrane Assays to Characterize Interaction of Drugs with ABCB1.

Authors:  Zsolt Fekete; Zsuzsanna Rajnai; Tünde Nagy; Katalin Tauberné Jakab; Anita Kurunczi; Katalin Gémes; Krisztina Herédi-Szabó; Ferenc Fülöp; Gábor K Tóth; Maciej Czerwinski; Greg Loewen; Peter Krajcsi
Journal:  J Membr Biol       Date:  2015-04-30       Impact factor: 1.843

Review 7.  The biology of the P-glycoproteins.

Authors:  C R Leveille-Webster; I M Arias
Journal:  J Membr Biol       Date:  1995-01       Impact factor: 1.843

Review 8.  Molecular analysis of the multidrug transporter.

Authors:  U A Germann
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

9.  The structure of P-glycoprotein and the secretion of lysosomal enzymes in multidrug-resistant cells.

Authors:  L Warren; A Malarska; J C Jardillier
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 10.  P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells.

Authors:  T Licht; I Pastan; M Gottesman; F Herrmann
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.